How Have Insiders Been Trading Amylyx Pharmaceuticals Inc. (AMLX) Stock?


Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) saw an upside of 6.70% to close Tuesday at $40.44 after adding $2.54 on the day. The 5-day average trading volume is 1,236,960 shares of the company’s common stock. It has gained $41.10 in the past week and touched a new high 3 times within the past 5 days. An average of 807,305 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 806,048.

AMLX’s 1-month performance is 13.76% or $4.88 on its low of $32.74 reached on 01/19/23. The company’s shares have touched a 52-week low of $6.51 and high of $39.78, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, AMLX has achieved 9.45% or $3.49 and has reached a new high 4 times. However, the current price is up 1.67% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

AMLX stock investors last saw insider trading activity on Sep 09.VIKING GLOBAL INVESTORS LP (10% Owner) most recently sold 700,000 shares at $30.23 per share on Sep 09. This transaction cost the insider $21,159,753. 10% Owner, VIKING GLOBAL INVESTORS LP, sold 700,000 shares at a price of $29.37 on Sep 08. Then, on Jul 06, 10% Owner ALS Invest 1 B.V. sold 60,609 shares at a price of $20.70 per share. This transaction amounted to $1,254,642.

Valuation Metrics

Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 8364.34 while the price-to-book (PB) in the most recent quarter is 16.44.

Amylyx Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 5.30, with the current ratio over the same period at 5.30.. In terms of profitability, the gross margin trailing 12 months is 50.10%. The firm’s gross profit as reported stood at $82.97 million against revenue of $0.28 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Amylyx Pharmaceuticals Inc.’s cash and short-term investments amounted to $54.86 million against total debt of $7.07 million. Net income grew 100.0% to -$53.76 million, while revenue of -$54.07 million was -0.58% off the previous quarter. Analysts expected AMLX to announce -$0.87 per share in earnings in its latest quarter, but it posted -$0.93, representing a -6.90% surprise. EBITDA for the quarter stood at more than -$54.6 million. AMLX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 37.41 million, with total debt at $7.07 million. Shareholders hold equity totaling $66.26 million.

Let’s look briefly at Amylyx Pharmaceuticals Inc. (AMLX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 68.98% to suggest the stock is trending Neutral, with historical volatility in this time period at 56.12%.

The stock’s 5-day moving average is $37.15, reflecting a +8.07% or $3.02 change from its current price. AMLX is currently trading +11.84% above its 20-day SMA, +68.29% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +16.84% and SMA200 by+193.90%.

Stochastic %K and %D was 86.14% and 68.51% and the average true range (ATR) pointed at 2.42. The RSI (14) points at 63.83%, while the 14-day stochastic is at 92.10% with the period’s ATR at 2.30. The stock’s 9-day MACD Oscillator is pointing at 1.28 and 1.69 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), BofA Securities launched coverage with a Buy rating. Analysts offering their rating for AMLX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate AMLX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.

What is AMLX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $43.00 and a high of $51.00, with their median price target at $50.00. Looking at these predictions, the average price target given by analysts is for Amylyx Pharmaceuticals Inc. (AMLX) stock is $48.80.


Please enter your comment!
Please enter your name here